Edgewise Receives U.S. FDA Fast Track Designation for EDG-5506 for the Treatment of Individuals with Becker Muscular Dystrophy (BMD)

Edgewise announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for EDG-5506 for the treatment of individuals with Becker muscular dystrophy, which confers the benefits that Fast Track designation provides. They are continuing to make good progress with their Phase 1 trial and will be enrolling a cohort of adults with Becker soon.

Please see the attached press release issued today for more information. For additional questions, contact info@edgewisetx.com.